Bausch Health Co. Inc. (BHC) Q4 Revenue Tops Views, Guidance Misses at Mid-Point
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Bausch Health Companies (BHC) PT Lowered to $25 at BMO Capital
February 21, 2019 9:35 AM ESTBMO Capital analyst Gary Nachman lowered the price target on Bausch Health Companies (NYSE: BHC) to $25.00 (from $26.00) while maintaining a Market Perform rating.
Nachman notes BHC delivered relatively in-line 4Q and 2019 guidance overall roughly in-line with expectations, although bottom-end of revenue range... More
